Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

• Status: Completed
• Trial end date: 2021-04-20
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis. The duration of study participation will be approximately 22 weeks, including up to a 6 week screening period, 12 week treatment period, and approximately 4 week follow up period. Approximately 280 participants are planned to be randomized into the study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: PF-06700841

Criteria

Inclusion Criteria:

• plaque psoriasis for 6 months

• PGA score mild or moderate

• body surface area (BSA) 2-15%

Exclusion Criteria:

• other skin conditions that would interfere with the evaluation of psoriasis

• history of herpes zoster or simplex

• Infected with Mycobacterium tuberculosis